MEET OUR BOARD OF DIRECTORS
Nanomab is guided by a highly experienced board of directors with decades of experience across the pharmaceutical and life science sectors.
Dr. Ting is a scientist, entrepreneur and angel investor. He has extensive experience in nuclear medicine and the Chinese healthcare sector. Most recently, he served as CEO and co-founder of Oxford Vacmedix and Biovue Technology Ltd. He was also the co-founder of Genemedix Plc., a biotechnology company once co-listed in main boards of LSE and SSE before its acquisition by the Reliance Group. Earlier in his career, he was the China General Manager of Amersham International Plc. and worked as a consultant for Westinghouse Electric, J&J and GE Healthcare. Dr. Ting received his DPhil degree from the University of Oxford, and held a permanent university senior research staff position under Professor J.E.Baldwin’s group before he left for industry.
Mr. Ho has over 30 years of operational, financial and capital market experience in industries that include healthcare & investment banking. Prior to joining NanoMab, he served as the GM of Ningbo JACO Pharmaceutical, and was responsible for its nuclear medicine product line expansion. He also served as director of Tasly Pharmaceutical Group and co-founded Oxford VacMedix. He held senior positions at various financial institutions, including Greater China head at Baring Asset Management Asia, Founder of Atlantis Investment Management Asia and China research head at Morgan Stanley, Merrill Lynch and UBS. He also had experience with publicly listed companies, including directorship at HK companies and CFO of a NASDAQ company. Mr. Ho holds a master’s degree in accounting and finance from Lancaster University, UK and is a fellow member of HKICPA.